Evidence map›Paper›PMID 41444785›Full record

ArticleScientific reports2025

Identification of bioactive phytoconstituents as promising ABL2 inhibitors using virtual screening and molecular dynamics simulation.

Afnan Elayyan Mousa Elayyan, Abdelbaset Mohamed Elasbali, Marwah Ayed Meshhin Alanazi, Anas Shamsi, Taj Mohammad

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Afnan Elayyan Mousa ElayyanDepartment of Clinical Laboratory, College of Applied Sciences-Qurayyat, Jouf University, 72388, Sakaka, Saudi Arabia.
Abdelbaset Mohamed ElasbaliDepartment of Clinical Laboratory, College of Applied Sciences-Qurayyat, Jouf University, 72388, Sakaka, Saudi Arabia. aeelasbali@ju.edu.sa.
Marwah Ayed Meshhin AlanaziThe Regional Laboratory & Central Blood Bank in Al-Qurayyat, 72388, Al-Qurayyat, Saudi Arabia.
Anas ShamsiCentre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates. anas.shamsi18@gmail.com.
Taj MohammadCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India. taj144796@st.jmi.ac.in.

Funding

Deanship of Graduate Studies and Scientific Research at Jouf University DGSSR-2025-FC-01023
6 · The paper itself

Abstract

ABL proto-oncogene 2 (ABL2) is an essential nonreceptor tyrosine kinase that regulates cytoskeletal dynamics, cell adhesion, and migration. ABL2 is dysregulated in multiple cancers and represents a promising therapeutic target. However, currently available tyrosine kinase inhibitors are limited by drug resistance and off-target effects. In this study, a structure-based virtual screening approach was performed to identify bioactive phytoconstituents with potential ABL2 inhibitory activity. An initial virtual screening of 11,908 natural compounds from the IMPPAT-2 library was conducted using molecular docking, and the best hits were subsequently filtered based on physicochemical and pharmacokinetic profiles. The top two compounds, Pachyrrhizin and Lupinisoflavone K, showed appreciable binding affinity with appropriate pharmacokinetic properties. Molecular dynamics simulations confirmed stable interactions within the ABL2 binding pocket, supported by hydrogen bonding throughout the simulation, suggesting constant binding of Pachyrrhizin and Lupinisoflavone K with ABL2. The conformational dynamics of these protein-ligand complexes were further confirmed by principal component analysis and free-energy landscape analysis. Overall, the findings suggest that Pachyrrhizin and Lupinisoflavone K may serve as potential ABL2 inhibitors, warranting further in vitro and in vivo validation.

Indexed as

PhytochemicalsProtein Kinase InhibitorsProtein-Tyrosine KinasesBinding SitesHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingProto-Oncogene MasARG tyrosine kinaseMAS1 protein, humanPhytochemicalsProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene MasABL2 inhibitorsCancerMolecular dynamics simulationPhytoconstituentsVirtual screening

Identifiers

PMID41444785
PMCPMC12738542

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.